Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749065 | 0.91 | NPC1 (0.33) | HTR2APIM1TP53KDM4ENPC1 | |
| SCHEMBL6747496 | 0.87 | TP53 (0.33) | HTR2ATP53ALDH1A1MAPK1KDM4E | |
| SCHEMBL7140092 | 0.77 | MTNR1A (0.39) | HTR2A | |
| SCHEMBL6749056 | 0.74 | CA12 (0.38) | TP53ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL6749798 | 0.72 | HTR1A (0.52) | HTR2AALDH1A1MAPK1 | |
| SCHEMBL6749081 | 0.71 | ALDH1A1 (0.50) | HTR2APIM1TP53ALDH1A1KDM4E | |
| SCHEMBL6752003 | 0.71 | ALDH1A1 (0.41) | TP53ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL5484265 | 0.70 | LMNA (0.42) | TP53ALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL6752165 | 0.69 | TNF (0.41) | TP53ALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL15985285 | 0.69 | HTR2A (0.69) | HTR2APIM1ALDH1A1MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | HTR2A 1996/4885PIM1 1193/4885TP53 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.